All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ITAC, 2022 0.80 [0.42; 1.52]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.78 [0.69 ; 0.88 ] ITAC, 2022, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 0% 4,929 moderate not evaluable death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ITAC, 2022 0.80 [0.42; 1.52]
Lopardo, 2021 0.57 [0.24; 1.37]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.78 [0.70 ; 0.87 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 2021, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 7 0% 7,268 moderate not evaluable deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
0.74 [0.55 ; 1.01 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022 2 0% 1,784 moderate not evaluable clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
Lopardo, 2021 1.61 [0.75; 3.49]
1.07 [0.97 ; 1.18 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 2021 4 0% 2,557 moderate not evaluable clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
0.98 [0.76 ; 1.26 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022 2 0% 899 moderate not evaluable death or ventilationdetailed results RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.79 [0.65 ; 0.95 ] RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 34% 4,280 moderate not evaluable hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.16 [0.97 ; 1.39 ] ACTIV-3/TICO LY-CoV555 , 2020, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 58% 4,664 moderate not evaluable ICU admissiondetailed results Lopardo, 2021 0.67 [0.35; 1.28]
0.67 [0.35 ; 1.28 ] Lopardo, 2021 1 0% 241 NA not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
1.09 [0.96 ; 1.25 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020 3 0% 1,028 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable serious adverse eventsdetailed results ITAC, 2022 0.98 [0.66; 1.46]
0.98 [0.66 ; 1.46 ] ITAC, 2022 1 0% 579 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-08 14:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
